FDA approves 'pill camera' to screen for colon cancer

accreditation
iStock
A kinder, gentler approach to one of the most dreaded cancer exams in medicine is on the way to help screen the large intestine of patients who are unable to complete their colonoscopies.

The bite-size, ingestible pill camera from Given Imaging is designed to help doctors spot polyps and other early signs of colon cancer. The Food and Drug Administration cleared the device for patients who have had trouble with the cringe-inducing procedure, which involves probing the colon using a tiny camera on a four-foot long, flexible tube.

The pill camera was previously approved in 80 other countries, including in Japan, Europe and Latin America.

The Israeli company's technology, developed from missile defence systems, uses a battery-powered camera to take high-speed photos as it slowly winds its way through the intestinal tract over eight hours. The images are transmitted to a recording device worn around the patient's waist and later reviewed by a doctor.

Read: Genes, obesity, colon cancer linked

A decade old

While Given's wireless, image-beaming system may sound like science fiction, it's actually more than a decade old. In 2001, the company received FDA approval for a similar device used to get a close-up view of the small intestine.

At that time, analysts expected Given's approach to grow into a direct competitor with traditional colonoscopy. But company studies found that the images taken by the mini-camera were not quite as clear as those from the in-office procedure. As a result, the company has pursued a more limited market for its PillCam: patients who have trouble undergoing standard colonoscopies.

Sales of over $60 million

The Food and Drug Administration approved the company's PillCam Colon for patients who have experienced an incomplete colonoscopy. The company estimates 750 000 US patients are not able to complete the procedure each year, due to anatomy issues, previous surgery or various colon diseases.

Even with this limited indication, analysts estimate the new pillcam could grow to sales of over $60 million in North America by 2019, with room for expansion as the technology improves. MorningStar analyst Debbie Wang said the company has shrewdly positioned the device as another tool in the gastrointestinal specialist's tool kit, rather than a direct competitor.

Read: The importance of a colonoscopy

"Given's management understands that the traditional colonoscopy is the gastroenterologist's bread and butter right now," Wang said. "So they didn't want to do anything that would position this as a substitute."

The pros of PillCam

Wang notes that Given's PillCam costs $500, significantly less than the $4,000 for a colonoscopy. Eventually, she thinks doctors may use the device to attract adults who avoid regular screenings due to fears of pain, embarrassment and general discomfort. The Centres for Disease Control and Prevention's guidelines currently recommend regular colonoscopies beginning at age 50 and continuing until age 75, though the majority of American adults don't follow the recommendations.

In December, Irish medical device firm Covidien said it was buying Given for about $860 million. Given, headquartered in Yoqneam, Israel, markets seven lines of medical devices and surgical supplies, including pillcams to screen the oesophagus and small intestine.


Read more:

Pill with camera detects cancer

Camera-pill takes pics inside body


We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
The ANC's leadership race is heating up. Who do you think will be elected party president at Nasrec in December?
Please select an option Oops! Something went wrong, please try again later.
Results
Nkosazana Dlamini-Zuma has got it in the bag
6% - 207 votes
I foresee a second term for Cyril Ramaphosa
81% - 2664 votes
Don’t discount a Zweli Mkhize win
12% - 407 votes
Vote
Rand - Dollar
18.02
-1.0%
Rand - Pound
19.94
-2.6%
Rand - Euro
17.63
-1.5%
Rand - Aus dollar
11.68
-0.4%
Rand - Yen
0.12
-0.8%
Gold
1,659.91
0.0%
Silver
18.72
-0.9%
Palladium
2,205.50
+2.5%
Platinum
867.00
+0.1%
Brent Crude
89.32
+3.4%
Top 40
56,921
-0.9%
All Share
63,264
-0.9%
Resource 10
59,793
+3.3%
Industrial 25
76,769
-2.2%
Financial 15
13,707
-2.8%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE